The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Drug: azathioprine     Quarter: 2016Q3

Total Drug/Injury Combinations: 480     Number of Pages: 24

DRUGNAME PT EventCount
AZATHIOPRINE. Therapy partial responder 1 view events
AZATHIOPRINE. Thrombocytopenia 1 view events
AZATHIOPRINE. Thrombocytosis 1 view events
AZATHIOPRINE. Transaminases increased 1 view events
AZATHIOPRINE. Transient ischaemic attack 1 view events
AZATHIOPRINE. Transplant failure 1 view events
AZATHIOPRINE. Treatment noncompliance 1 view events
AZATHIOPRINE. Tuberculosis 1 view events
AZATHIOPRINE. Umbilical cord abnormality 1 view events
AZATHIOPRINE. Ureteral necrosis 1 view events
AZATHIOPRINE. Urosepsis 1 view events
AZATHIOPRINE. Uterine haemorrhage 1 view events
AZATHIOPRINE. Varicocele 1 view events
AZATHIOPRINE. Vertigo 1 view events
AZATHIOPRINE. Vision blurred 1 view events
AZATHIOPRINE. Weight increased 1 view events
AZATHIOPRINE. White blood cell count decreased 1 view events
AZATHIOPRINE. White matter lesion 1 view events
AZATHIOPRINE. Wound dehiscence 1 view events
AZATHIOPRINE. Yellow skin 1 view events

Total Drug/Injury Combinations: 480     Number of Pages: 24

NOTE: EventCount numbers on this page include duplicate entries from event reports. (e.g. One event has DrugX entered twice, which equals 2 on this page.) The "view events" page treats these duplicates as single entries. (e.g. The 2 entries of DrugX for a single event are counted as 1 instance.)